Abstract:Background: Although JAK (Janus Kinase) inhibitors have been widely applied to many types of aggressive tumors with continuously activated JAK/STAT signaling pathways, efficacious compounds against cervical cancer (CC) are still lacking, and chronic exposure to them inevitably results in drug resistance that often arises from compensatory activation of alternative signaling and survival pathways. Therefore, developing novel JAK inhibitors and identifying their partner compounds for combination therapy against CC, remains an unmet clinical need.Methods: In this study, by virtual screening the SPECS database, we selected out multiple JAK inhibitor candidates, validated their kinase activities and antitumor drug efficacies in various biochemical, cellular and in vivo xenograft models. Next, we screened a chemical library containing 2094 small molecules to identify compounds that act synergistically with the best JAK inhibitor obtained above in dampening CC cell propagation. Finally, the molecular mechanism of such synergistic effect was explored.Findings: Twenty potential small-molecule JAK inhibitors were identified by virtual screening, and the top 9 ranking compounds were validated by biochemical assays. AH057, the best JAK inhibitor identified, can effectively block JAK/STAT pathways by directly inhibiting JAK1/2 activities, and exhibits potent antitumor effects including compromised cell proliferation and invasion, increased apoptosis, arrested cell cycles and impaired tumor progression in a xenograft model. Among all cell lines examined, CC cell lines were the most sensitive to AH057. Further, based on the calculated Bliss synergy scores, SGI-1027, a DNMT1 inhibitor, was identified as the best compound that works in high synergy with AH057. The combination of AH057 and SGI-1027 potently induced cell cycle arrest at G1 phase partially through Cyclin D1 and Cyclin A2, and apoptotic cell death that is linked to PARP, Caspase-3, Bcl-xL and Survivin.Interpretation: A novel oral small-molecule JAK1/2 inhibitor AH057 with definitive antitumor efficacy against CC is identified in this study. The combination of AH057 with the DNMT1 inhibitor SGI-1027 synergistically impairs cancer cell propagation via induced apoptosis and cell cycle arrest, likely by acting on a same group of downstream effector molecules that are dually controlled by JAK1/2 and DNMT1. This study provides preclinical support for launching a clinical trial to evaluate the safety and efficacy of this drug combination in patients with CC and other malignant tumors.Funding Statement: This work was supported by grants from the National Key Research and Development Program of China (2016YFA0101201, 2016YFA0100303, 2017YFD0200505), and the National Natural Science Foundation of China (31601103, 31872022).Declaration of Interests: YJW, BK and JZ have a pending patent application titled “Identification of a novel JAK1/2 inhibitor and its synergistic drug combinations against human cancers”. The other authors declared no conflicts of interest.Ethical Approval Statement: The Experimental Animal Ethics Committee of Zhejiang University has approved the animal protocol.

New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation

Type II mode of JAK2 inhibition and destabilization are potential therapeutic approaches against the ruxolitinib resistance driven myeloproliferative neoplasms

How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study

Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms

JAK2 inhibitors for the treatment of Philadelphia-negative myeloproliferative neoplasms: current status and future directions

Molecular basis of JAK2 H608Y and H608N mutations in the pathology of acute myeloid leukemia

Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/Stat pathway.

Identification of a Novel Oral Small-Molecule JAK1/2 Inhibitor and Its Potent Synergistic Drug Combinations Against Cervical Cancer

Functional and Structural Characterization of Clinical-Stage Janus Kinase 2 Inhibitors Identifies Determinants for Drug Selectivity

N -(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms

New advances in the role of JAK2 V617F mutation in myeloproliferative neoplasms

Amino Acid Residue E543 in Jak2 C618r is A Potential Therapeutic Target for Myeloproliferative Disorders Caused by Jak2 C618r Mutation

Janus kinase 2 inhibitors in myeloproliferative disorders

The Effects of R683S (G) Genetic Mutations on the JAK2 Activity, Structure and Stability.

Discovery and optimization of 2-aminopyridine derivatives as novel and selective JAK2 inhibitors.

Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasms

Design, synthesis and SAR study of 2-aminopyridine derivatives as potent and selective JAK2 inhibitors

Molecular modeling of novel 2-aminopyridine derivatives as potential JAK2 inhibitors: a rational strategy for promising anticancer agents

Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling

Conversion of a False Virtual Screen Hit into Selective JAK2 JH2 Domain Binders Using Convergent Design Strategies

3089 – ELUCIDATING NEW MECHANISMS OF ACQUIRED RESISTANCE TO IDH INHIBITION BY SATURATION VARIANT SCREENING OF BASE-EDITED LEUKEMIA CELLS